The organ effects of systemic inflammation response activated during open heart surgery and current treatment methods;Açik Kalp Cerrahisi Esnasinda Aktive Olan Sistemik ̇ Inflamasyon Cevabinin Organ Fonksiyonlarina Etkileri ve Güncel Tedavi Yötemleri

Anadolu Kardiyoloji Dergisi

Volumn 4, Issue 3, 2004, Pages 231-235

  Iriz, Erkan ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Open heart surgery; Systemic inflammation

Indexed keywords

ALPHA TOCOPHEROL; AMRINONE; ANTIOXIDANT; APROTININ; ASCORBIC ACID; COMPLEMENT; CORTICOSTEROID; CYTOKINE; ENDOTHELIN; ENDOTOXIN; HEPARIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MILRINONE; MONOCLONAL ANTIBODY; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; CARDIOPULMONARY BYPASS; CENTRAL NERVOUS SYSTEM DISEASE; COMPLEMENT ACTIVATION; ENDOTOXEMIA; FOREIGN BODY REACTION; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MULTIPLE ORGAN FAILURE; OPEN HEART SURGERY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; REPERFUSION INJURY; REVIEW; SURGICAL INJURY; SURGICAL TECHNIQUE; ULTRAFILTRATION;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HUMANS; INFLAMMATION; POSTOPERATIVE COMPLICATIONS;

EID: 4644311966     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Gu JY, Mariani MA, Boonstra PW, Grandjean JG, van Overen W. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass. Chest 1999; 116: 892-8.
2. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylotoxins. N Engl J Med 1981; 304: 497-503.
3. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997; 96: 3542-8.
4. Soslau G, Morgan DA, Jaffe JA, Brodsky I, Wang Y. Cytokine m-RNA expression in human platelets and a megakaryocytic cell line and cytokine modulation of platelet function. Cytokine 1997; 9: 405-11.
5. Montovani A, Sozzani S, Vecchi A, Introna M, Allavena P. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 1997; 78: 406-14.
6. Teoh KH, Bradley CA, Gauldie J, Burrows H. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation 1995; 92 (Suppl II): 347-53.
7. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin-1 beta synergistically depress human myocardial function. Crit Care Med 1999; 27: 1309-18.
8. Worrall NK, Chang K, Lejeunne WS, et al. TNF-α causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and-independent mechanisms. Am J Physiol 1997; 273: H2565-74.
9. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res 1999; 85: 185-99.
10. Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonry bypass. J Am Med Assoc 1996; 275: 1007-12.
11. Jirik FR, Podor TJ, Hirano T, et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989; 142: 144-7.
12. Sato H, Zhao ZQ, Todd JC, et al. Basal nitric oxide expresses endogenous cardioprotection during reperfusion by inhibition of neutrophil-mediated damage after surgical revascularization. J Thorac Cardiovasc Surg 1997; 113: 399-409.
13. Oyama J, Shimokawa H, Momii H, et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 1998; 101: 2207-14.
14. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24: 1131-8.
15. Jordan JE, Zhao ZQ, Vinten Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999; 43: 860-78.
16. Zahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF. Acute cardiac inflammatory response to postischemic reperfusion during cardiopulmonary bypass. Cardiovasc Res 1999; 41: 722-30.
17. Stammberger U, Gaspert A, Hillinger S, et al. Apoptosis induced by ischemia and reperfusion in experimental lung transplantation. Ann Thorac Surg 2000; 69: 1532-6.
18. MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 1997; 81: 137-44.
19. Aebert H, Kirchner S, Birnbaum DE, Holler E, Andreesen R, Eissner G. Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass. Eur J Cardiothorac Surg 2000; 18: 589-93.
20. Kayaalti B, Büket S. Açik kalp cerrahisinde beyin dolaşimi ve korunmasi. Türk Anest ve Rean Cem Mecmuasi 1992; 20: 68-72.
21. Shaaban Ali M, Harmer M, Vaughan R. Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth 2000; 85: 287-98.
22. Edmunds LH. Cardiopulmonary bypass for open heart surgery. In: Baue AE, Geha AS, Hammond GL, Laks H, Naunheim KS, editors. Glenn's Thoracic and Cardiovascular Surgery. 6th ed. Stamford, CT: Appleton and Lange; 1996. p. 1163-52.
23. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. Chest 2001; 119: 884-8
24. Paşaoǧlu I. Ekstrakorporeal Dolaşim. In: Bozer AY, editör. Kalp Hastaliklari ve Cerrahisi. Ankara: Ayyildiz Matbaasi; 1985. p. 101-23.
25. del Castillo CF, Harringer W, Warshaw AL, et al. Risk factors of pancreatic cellular injury after cardiopulmonary bypass. N Eng J Med 1991; 325: 382-7.
26. Kayaalp O. Tibbi Farmakoloji-Hemostatik ilaçlar, Istanbul: Feryal Matbaasi; 1988.
27. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110: 1658-62.
28. Levi M, Cromheecke Me, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7.
29. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 2000; 120: 361-9.
30. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996; 83: 696-700.
31. Hall RI, Stafford Smith M, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997; 85: 766-82.
32. Kawamura T, Inada K, Nara N, Wakusawa R, Endo S. Influence of methylprednisolone on cytokine balance during cardiac surgery. Crit Care Med 1999; 27: 545-8.
33. Wan S, LeClerc JL, Huynh CH, et al. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass? J Thorac Cardiovasc Surg 1999; 117: 1004-8.
34. Hill GE, Alonso A, Thiele G, Robbins R. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 1994; 79: 23-7.
35. Steer JH, Kroeger KM, Abraham LJ, Joyce DA. Glucocorticoids suppress TNF-α expression by human monocytic THP-1 cells by supressing transactivation through adjacent NF-kB and c-Jun/ATF-2 binding sites in the promoter. J Biol Chem 2000; 275: 18432-40.
36. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth 1999; 13 (Suppl 1): 13-29.
37. Tyrrel DJ, Horne AP, Holme KR, Preuss JM, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
38. Rathmell JP, Prielipp RC, Butterworth JF, et al. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesth Analg 1998; 86: 683-90.
39. Takeuchi K, del Nido PJ, Ibrahim AE, et al. Vesnarinone and amrinone reduce systemic inflammatory response syndrome. J Thorac Cardiovasc Surg 1999; 117: 375-82.
40. Hayashida N, Tomoeda H, Oda T, et al. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 1999; 69: 1661-7.
41. Seghaye MC, Duchateau J, Grabitz RG, et al. Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: a clinical and experimental study. J Thorac Cardiovasc Surg 1996; 111: 882-92.
42. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100: 2499-506.
43. Wan S, Le Clerc JL, Antoine M, DeSmet JM, Yim AP, Vincent JL. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized trials. Ann Thorac Surg 1999; 68: 1230-5.
44. Ovrum E, Brosstad F, Holen EA, Tangen G, Abdelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995; 92: 2579-84.
45. Dickinson TA, Prichard J, Rieckens F. A comparison of the benefit of roller pump versus constrained vortex pump in adult open-heart operations utilizing outcomes research. J Extra Corpor Technol 1994; 26: 108-13.
46. Iriz Erkan. Deǧişik Prime Solüsyonlarin serebral etkilerinin serum S-100B protein ve bilişsel kognitif testlerle deǧerlendirilmesi (Uzmanlik Tezi). Samsun: Ondokuz Mayis Ü niv.; 2001.
47. Kaplan SS, Park TS, Gonzales ER, Gidday JM. Hydroxyethyl starch reduces leukocyte adherence and vascular injury in the newborn pig cerebral circulation after asphyxia. Stroke 2000; 31: 2218-23.
48. Hofbauer R, Moser D, Hornykewycz S, Frass M, Kapiotis S. Hydroxyethyl starch reduces the chemotaxis of white cells through endothelial cell monolayers. Transfusion 1999; 39: 289-94.
49. Journois D, Pouard P, Greeley WJ, Mouriat P, Vouhe P, Safran D. Hemofiltration in pediatric cardiac surgery. Anesthesiology 1994; 81: 111-9.
50. Grunefelder J, Zund G, Schoeberlein A, et al. Modified ultrafiltration lowers adhesion molecules and cytokine levels after cardiopulmonary bypass without clinical relevance in adults. Eur J Cardiothorac Surg 2000; 17: 77-83.
51. Menasche P, Peynet J, Haeffner-Cavaillon N, et al. Influence of temperature on neutrophil traffic during clinical cardiopulmonary bypass. Circulation 1995; 92 (Suppl II): 334-40.
52. Le Deist F, Menasche P, Kucharsky C, Bel A, Piwinca A, Bloch G. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion. A clinical study. Circulation 1995; 92 (Suppl II): 354-8.
53. Birdi I, Caputo M, Underwood M, Bryan AG, Angelini GD. The effects of cardiopulmonary bypass temperature on inflammatory response following cardiopulmonary bypass. Eur J Cardiothorac Surg 1999; 16: 540-5.
54. Medina J, Wolf A. Strategies to antagonise the cyclosporine A induced proliferation of human pulmonary artery smooth muscle cell anti-endothelin-1 antibodies, verapamil, and octreotide. Biochem Pharmacol 2000: 1; 59: 1459-66.
55. Mukhopadhyay A, Manna SK, Aggarwal BB. Pervanadate-induced Nuclear Factor kB activation requires tyrosine phosphorylation and degredation of I kB-alfa. Comparison with Tumor Necrosis Factor-alfa. J Biol Chem 2000; 24: 8549-55.
56. Babinska A, Kedees MH, Athar H, et al. F11-receptor (F11R/JAM) mediates platelet adhesion to endothelial cells: Role in inflammatory thrombosis. Thromb Haemost. 2002; 88: 843-50.
57. Wan S, Arifi AA, Wan IY, Ng CS, Lee TW, Yim AP. Cytokine responses to myocardial revascularization on cardiopulmonary bypass: intermittent cross-clamping versus blood cardioplegic arrest. Ann Thorac Cardiovasc Surg. 2002; 8: 12-7.
58. Holmes JH., Connoly NC, Paull DL., et al. Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm Res 2002: 51; 579-86.